New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|April 15, 2008
The American Journal of Managed Care
- April 2008
- Volume 14
- Issue 4
Strand V, Singh JA. (Am J Manag Care. 2007;13[suppl 9]:S237-S251)
Advertisement
After the publication of our December 2007 supplement, “Health-related Quality of Life in Rheumatoid Arthritis,” the Editors learned that several authors were not given the opportunity to review the final proofs of their manuscripts. As a result, errors were subsequently identified. Due to the extent of the errors in the article by Strand et al, “Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials,” we have printed the corrected article in our April issue.
to see a corrected version of this article.
Articles in this issue
over 18 years ago
Furst DE, Khanna D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217.over 18 years ago
Strand V, Singh JA. (Am J Manag Care. 2007;[suppl 9]:S237-S251.over 18 years ago
Furst, DE; Khanna, D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217)over 18 years ago
Association of Insurance Coverage With Chlamydia ScreeningAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Secondary T-Cell Cancers After CAR T: Rare, Real, and Worth Watching
4
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
5